Efforts needed to stop the spread of carbapenem-resistant Acinetobacter baumannii

Efforts needed to stop the spread of carbapenem-resistant Acinetobacter baumannii
Percentage (%) of invasive Acinetobacter spp. isolates with resistance to carbapenems, bycountry, EU/EEA countries, 2014 (A) and 2015 (B). Credit: European Centre for Disease Prevention and Control

ECDC's latest risk assessment highlights the need of increased efforts to face this significant threat to patients and healthcare systems in all EU/EEA countries and outlines options to reduce risks through clinical management, prevention of transmission in hospitals and other health-care settings, prevention of cross-border transmission, and improvement of preparedness of EU/EEA countries.

Acinetobacter baumannii is the cause of difficult-to-treat infections in healthcare settings in Europe due to its increasing resistance to antimicrobial agents, in particular the carbapenems. Outbreaks of carbapenem-resistant A. baumannii in healthcare facilities have been reported in Europe and worldwide.

Infections with carbapenem-resistant A. baumannii occur in patients with severe underlying diseases, mainly in intensive care units, and are often related to invasive procedures or indwelling devices. However, such infections are increasingly being reported in patients admitted to conventional medical and surgical wards. A. baumannii is difficult to eradicate once it has become endemic.

Recent ECDC data from the European survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE) project and from the European Antimicrobial Resistance Surveillance Network (EARS-Net) confirmed that although there is already a high resistance baseline in some countries, there has been an overall increase of carbapenem-resistant A. baumannii in Europe.

These data confirm an already alarming situation that continues to worsen in many EU/EEA countries. While carbapenems traditionally were the antibiotics of choice for treatment of A. baumannii infections, resistance to these drugs has led to increased use of colistin as last-line treatment. Although still rare, resistance to colistin in A. baumannii is also increasingly being reported in Europe.

ECDC's highlights the need of increased efforts to face this significant threat to patients and healthcare systems in all EU/EEA countries and outlines options to reduce risks through , prevention of transmission in hospitals and other , prevention of cross-border transmission, and improvement of preparedness of EU/EEA .


Explore further

ECDC rapid risk assessment outlines actions to reduce the spread of the mcr-1 gene

Provided by European Centre for Disease Prevention and Control (ECDC)
Citation: Efforts needed to stop the spread of carbapenem-resistant Acinetobacter baumannii (2016, December 14) retrieved 26 June 2019 from https://medicalxpress.com/news/2016-12-efforts-carbapenem-resistant-acinetobacter-baumannii.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more